- Details
- Description
-
Packaging Size30t/Bottle
-
Strength200mg
-
CompositonCenobamate
-
TreatmentPartial-onset Seizures
-
FormTablet
-
BrandLuciCeno
-
Quantity Unit200mg*30t/Box
-
ManufacturerLucius Pharmaceuticals (Lao) Co.,Ltd
About Cenobamate
Cenobamate works as an anticonvulsant by regulating irregular electrical brain signals. It can be used on its own to treat partial-onset seizures or can be used with other anti-seizure medications. The cenobamate mechanism of action (MOA) is thought to be inhibiting voltage-gated sodium channels and positively affects the γ-aminobutyric acid (GABAA) ion channel. Some people may have their seizures reduced to zero. Cenobamate drug class is an anticonvulsant.
Partial-onset Seizures
Indicated for treatment of partial-onset seizures as either monotherapy or adjunctive therapy
Dose and titration schedule
- Do not exceed recommended dosage and titration, owing to potential for serious adverse reactions
- Weeks 1-2: 12.5 mg PO qDay initially
-
Titration dose
- Weeks 3-4: 25 mg PO qDay
- Weeks 5-6: 50 mg PO qDay
- Weeks 7-8: 100 mg PO qDay
- Weeks 9-10 150 mg PO qDay
-
Maintenance dose
- Week 11 and thereafter: 200 mg PO qDay
-
Maximum dose
- Based on clinical response and tolerability, dose may be increased above 200 mg by increments of 50 mg/day q2week to 400 mg PO qDay if needed
Dosage Modifications
Renal impairment
- Mild, moderate, or severe: Caution advised; consider dosage reduction
- End-stage renal disease: Not recommended
Hepatic impairment
- Mild-to-moderate (Child-Pugh 5-9): Not to exceed 200 mg/day; additional dosage reduction may be necessary
- Severe: Not recommended
